Annexon Inc (ANNX)

Overview Chart Financials Statistics Earnings Insider transactions ETFs News

News

Real-time news feed aggregating press releases, regulatory filings, and global media coverage for a single company, filterable by date range, relevance score, and sentiment classification. Each article is tagged with company-specific and overall market sentiment — allowing investors to separate fundamental catalysts from broader market noise and monitor how the narrative around a stock is evolving over time.

Sep 26, 2026

Annexon (ANNX) President and CEO Douglas Love Buys 26,065 Shares

Douglas Love, President and CEO of Annexon Inc (ANNX), recently purchased 26,065 shares of the company on September 24, 2026, increasing his total holdings to 390,476 shares. The transaction, valued at $3.83 per share, signals confidence from the executive in the clinical-stage biopharmaceutical company, which focuses on developing treatments for autoimmune, neurodegenerative, and ophthalmic diseases. This insider buy contributes to a slightly positive insider activity trend for Annexon over the past year, with 12 buys versus 10 sells.